afatinib,trastuzumab deruxtecan,pembrolizumab,cetuximab,adagrasib,fruquintinib
daiichi sankyo,boehringer ingelheim,eli lilly,hutchmed,mirati,merck,astrazeneca
['cetuximab', 'fresco-2', 'adagrasib', 'lba25', 'fruquintinib', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'krystal-1', 'lba24']
two abstracts to look out for at #esmo2022! lba24 #krystal-1 #adagrasib w/, w/o #cetuximab in pts with advanced #crc w/ #krasg12c mutation lba25 #fresco-2 a phase iii mrct of #fruquintinib in pts w/ refractory #mcrc 12/9/22, f camp auditorium #meded 
Independent and international experts in GI oncology supporting medical oncologists to give the best possible care to patients. Part of https://t.co/Y8pV8OaxOB